Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Larsucosterol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Larsucosterol 30 mg | EXPERIMENTAL | Participants will receive Larsucosterol 30 milligrams (mg) intravenous infusion on Day 1. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive intravenous infusion of placebo matched to Larsucosterol on Day 1. |
| Name | Type | Description |
|---|---|---|
| Larsucosterol | DRUG | Larsucosterol intravenous infusion. |
| Placebo | DRUG | Matching-placebo (sterile water for injection) intravenous infusion. |
Inclusion Criteria- A participant will be eligible for inclusion in this study if he/she meets all the following criteria: 1. Able to provide written informed consent (either from participant or participant's legally acceptable representative). 2. Onset of jaundice within 8 weeks before hospital a...
Larsucosterol is an investigational small molecule being developed for the treatment of hepatitis, specifically alcohol-associated hepatitis. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Larsucosterol is being developed by Bausch Health Companies Inc., a company traded on the stock exchange under the ticker symbol BHC.
Larsucosterol is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved for any use.
Larsucosterol is being studied in a Phase 3 clinical trial with the identifier NCT07428538. This randomized, double-blind, placebo-controlled trial is evaluating the safety and efficacy of Larsucosterol in participants with alcohol-associated hepatitis and is currently recruiting participants in the United States.
The specific molecular target of Larsucosterol has not been disclosed in available information, so its mechanism of action is not described here.